|Population pharmacokinetics of remifentanil in patients undergoing orthotopic liver transplantation|
|Zhang Li-ping1; Yang Lu1; Bi Shan-shan4; Lu Wei4; Zhang Xian-hua2; Zhai Suo-di2; Duan Li-ping3|
|关键词||remifentanil liver transplantation pharmacokinetics anesthesia|
|刊名||CHINESE MEDICAL JOURNAL|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal|
|研究领域[WOS]||General & Internal Medicine|
|关键词[WOS]||ADULT MALE-VOLUNTEERS ; CARDIOPULMONARY BYPASS ; HUMAN BLOOD ; PHARMACODYNAMICS ; GI87084B ; SURGERY ; MODEL ; AGE|
Backgroud Little is known about the influence of liver transplantation on the pharmacokinetics of most anesthetic drugs. The goal of this study was to study the population pharmacokinetics of remifentanil in the different phases of orthotopic liver transplantation (OLT) and the influence of relevant factors.
Methods Thirteen adult patients undergoing OLT were enrolled. A single bolus infusion of remifentanil 5 mu g/kg was administered during the preanhepatic, anhepatic and neohepatic phases of OLT. Arterial blood samples of 1.5 ml were collected at 0 (baseline), 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 45, 60 and 90 minutes after drug administration. Remifentanil concentration was assayed by high-performance liquid chromatography/mass spectrometry/mass spectrometry (HPLC/MS/MS). Population pharmacokinetic modeling was performed using nonlinear mixed-effects modeling (NONMEM).
Results The pharmacokinetics of remifentanil in patients undergoing OLT was best described by a two-compartment open model. The pharmacokinetic parameters were not influenced by age, gender, operative phase, blood temperature, rehydration volume, or blood loss volume during sampling. The volume of distribution in the central compartment (Vi) and the volume of distribution in the peripheral compartment (V(2)) were influenced by body weight.
Conclusions The population pharmacokinetics of remifentanil in patients undergoing OLT can be well described by a two-compartment open model. The functional status of the liver does not significantly affect the pharmacokinetics of remifentanil, but the body weight is an influential factor of V(1) and V(2). Chin Med J 2009,122(9):1032-1038
|作者单位||1.Peking Univ, Hosp 3, Dept Pharm, Beijing 100191, Peoples R China|
2.Peking Univ, Hosp 3, Dept Anesthesiol, Beijing 100191, Peoples R China
3.Peking Univ, Hosp 3, Dept Gastroenterol, Beijing 100191, Peoples R China
4.Peking Univ, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
|Zhang Li-ping,Yang Lu,Bi Shan-shan,et al. Population pharmacokinetics of remifentanil in patients undergoing orthotopic liver transplantation[J]. CHINESE MEDICAL JOURNAL,2009,122(9):1032-1038.|
|APA||Zhang Li-ping.,Yang Lu.,Bi Shan-shan.,Lu Wei.,Zhang Xian-hua.,...&Duan Li-ping.(2009).Population pharmacokinetics of remifentanil in patients undergoing orthotopic liver transplantation.CHINESE MEDICAL JOURNAL,122(9),1032-1038.|
|MLA||Zhang Li-ping,et al."Population pharmacokinetics of remifentanil in patients undergoing orthotopic liver transplantation".CHINESE MEDICAL JOURNAL 122.9(2009):1032-1038.|